Macular Degeneration Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Anti-VEGF (Vascular Endothelial Growth Factor) Agents, Anti-Inflammatory Agents (Corticosteroids), Complement Inhibitors; Product Type; By Treatment Type; Key Players

Datasheet

$ 1999.00